# US 2008/0076930 A1 · Novel stereoselective synthesis of benzimidazole sulfoxides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076930 A1
- Document ID: US20080076930A1
- Status: Published application
- Kind: A1
- Application number: 11/865,312
- Filed: 2007-10-01
- Published: 2008-03-27
- Earliest claimed: 2004-08-06
- Assignees: Hetero Drugs Limited
- Inventors: Bandi Reddy; Kura Reddy; Rapolu Reddy; Dasari Reddy
- Web page: https://patentgrep.com/patent/US20080076930A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a process for stereoselective synthesis of substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole is reacted with (R)-camphorsulfonyl chloride to form a mixture of 1-(R)-camphorsulfonyl-5- (and 6-)methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-1H-benzimidazole, oxidized to obtain a diastereomeric excess of 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole over 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(R)-sulfinyl]-1H-benzimidazole, the diastereomers are separated by fractional crystallization and the separated 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole is deprotected to give esomeprazole.

## Claims

### Claim at position 1

1-92. (canceled)

### Claim 93

Substantially pure compounds of formula VIa to VId:
wherein
R is
X is
and
R1-R4 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R1- R4 form ring structures which may be further substituted;
wherein
R5 and R7 are same or different and selected from hydrogen, alkyl, alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R6 is selected from hydrogen, alkyl, alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, nitro, phenylalkyl and phenylalkoxy;
R8 is hydrogen or forms an alkylene chain together with R7 and R9 and R10 are, same or different and selected from hydrogen, halogen and alkyl; Rc is a chiral moiety having at least one asymmetric center and at least one asymmetric center in the chiral moiety can have either R or S configuration;
Z is:
with the proviso that at least one of R1 to R4 is different from any of the rest of them provided if R1 and R4 are same, R2 and R3 are different; or if R2 and R3 are same, R1 and R4 are different.

### Claim 94 (depends on 93)

The compounds of claim 93, wherein R is

### Claim 95 (depends on 93)

The compounds of claim 93, wherein X is —CH2.

### Claim 96 (depends on 93)

The compounds of formula VIa to VId of claim 93, wherein R is
R1═R3═R4═H; R2 is —OCH3 and X is —CH2.

### Claim 97 (depends on 93, 94, 95, 96)

The compounds of claims 93 to 96, wherein Z is

### Claim 98 (depends on 93, 94, 95, 96)

The compounds of claims 93 to 96, wherein Rc-Z- of formulas VIa to VId are selected from (S) or (R)-camphor sulfonyl, (S)- or (R)-glycidylsulfonyl-, D- or L-mandeloyl, a stereo isomeric 1-(ethoxycarbonyl)-3-phenylpropylalanyl, (D) or (L)-phenyl alanyl and (D) or (L)-alanyl.

### Claim 99 (depends on 98)

The compounds of claim 98, wherein Rc-Z- is (S) or (R)-camphor sulfonyl.

### Claim 100 (depends on 99)

The compounds of claim 99, wherein Rc-Z- is (R)-camphor sulfonyl.

### Claim 101

(canceled)

### Claim 102

(canceled)

### Claim 103

(canceled)

### Claim 104

Benzimidazole sulfides of formula IV:
wherein
R is
X is
and
R1-R4 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R1-R4 form ring structures which may be further substituted:
wherein
R5 and R7 are same or different and selected from hydrogen, alkyl, alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R6 is selected from hydrogen, alkyl alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, nitro, phenylalkyl and phenylalkoxy;
R8 is hydrogen or forms an alkylene chain together with R7 and R9 and R10 are, same or different and selected from hydrogen, halogen and alkyl; Rc is a chiral moiety having at least one asymmetric center and at least one asymmetric center in the chiral moiety can have either R or S configuration:
Z is:
with the proviso that at least one of R1 to R4 is different from any of the rest of them provided if R1 and R4 are same, R2 and R3 are different; or if R2 and R3 are same, R1 and R4 are different.

### Claim 105 (depends on 104)

The compounds of claim 104, wherein X is —CH2 and R is

### Claim 106 (depends on 104)

The compounds of claim 104, wherein R is
R1═R3═R4═H; R2 is —OCH3 and X is —CH2.

### Claim 107 (depends on 104, 105, 106)

The compounds of claims 104 to 106, wherein Z is

### Claim 108 (depends on 104, 105, 106)

The compounds of claims 104 to 106, wherein Rc-Z- of formula IV is selected from (S) or (R)-camphor sulfonyl, (S)- or (R)-glycidylsulfony-, D- or L-mandeloyl, a stereo isomeric 1-(ethoxycarbonyl)-3-phenylpropylalanyl, (D) or (L)-phenyl alanyl and (D) or (L)-alanyl.

### Claim 109 (depends on 108)

The compounds of claim 108, wherein Rc-Z- is (S) or (R)-camphor sulfonyl.

### Claim 110 (depends on 109)

The compounds of claim 109, wherein Rc-Z- is (R)-camphor sulfonyl.

### Claim 111

Compounds of formula IVa and IVb in substantially pure form:
wherein
R is
X is
and
R1-R4 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R1-R4 form ring structures which may be further substituted;
wherein
R5 and R7 are same or different and selected from hydrogen, alkyl, alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;
R6 is selected from hydrogen, alkyl, alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, nitro, phenylalkyl and phenylalkoxy;
R8 is hydrogen or forms an alkylene chain together with R7 and R9 and R10 are, same or different and selected from hydrogen, halogen and alkyl; Rc is a chiral moiety having at least one asymmetric center and at least one asymmetric center in the chiral moiety can have either R or S configuration;
Z is:
with the proviso that at least one of R1 to R4 is different from any of the rest of them provided if R1 and R4 are same, R2 and R3 are different; or if R2 and R3 are same, R1 and R4 are different.

### Claim 112 (depends on 111)

The compounds of claim 111, wherein X is —CH2 and R is

### Claim 113 (depends on 111)

The compounds of claim 111, wherein R is
R1═R3═R4═H; R2 is —OCH3 and X is —CH2.

### Claim 114 (depends on 111, 112, 113)

The compounds of claims 111 to 113, wherein Z is

### Claim 115 (depends on 111, 112, 113)

The compounds of claims 111 to 113, wherein Rc-Z- of formulas Via to VId are selected from (S) or (R)-camphor sulfonyl, (S)- or (R)-glycidylsulfonyl-, D- or L-mandeloyl, a stereo isomeric 1-(ethoxycarbonyl)-3-phenylpropylalanyl, (D) or (L)-phenyl alanyl and (D) or (L)-alanyl.

### Claim 116 (depends on 115)

The compounds of claim 115, wherein Rc-Z- is (S) or (R)-camphor sulfonyl.

### Claim 117 (depends on 116)

The compounds of claim 116, wherein Rc-Z- is (R)-camphor sulfonyl.
